*Department of Surgery, Kantonsspital St Gallen, St Gallen, Switzerland †Department of General, Abdominal and Transplant Surgery ‡Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany §University Clinic for Visceral Surgery and Medicine, University Hospital Berne, Berne, Switzerland ¶Department of Surgery, Duke University Medical Center, Durham, NC; and ‖Division of Medical Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.
Ann Surg. 2015 Jul;262(1):112-20. doi: 10.1097/SLA.0000000000000860.
To assess whether palliative primary tumor resection in colorectal cancer patients with incurable stage IV disease is associated with improved survival.
There is a heated debate regarding whether or not an asymptomatic primary tumor should be removed in patients with incurable stage IV colorectal disease.
Stage IV colorectal cancer patients were identified in the Surveillance, Epidemiology, and End Results database between 1998 and 2009. Patients undergoing surgery to metastatic sites were excluded. Overall survival and cancer-specific survival were compared between patients with and without palliative primary tumor resection using risk-adjusted Cox proportional hazard regression models and stratified propensity score methods.
Overall, 37,793 stage IV colorectal cancer patients were identified. Of those, 23,004 (60.9%) underwent palliative primary tumor resection. The rate of patients undergoing palliative primary cancer resection decreased from 68.4% in 1998 to 50.7% in 2009 (P < 0.001). In Cox regression analysis after propensity score matching primary cancer resection was associated with a significantly improved overall survival [hazard ratio (HR) of death = 0.40, 95% confidence interval (CI) = 0.39-0.42, P < 0.001] and cancer-specific survival (HR of death = 0.39, 95% CI = 0.38-0.40, P < 0.001). The benefit of palliative primary cancer resection persisted during the time period 1998 to 2009 with HRs equal to or less than 0.47 for both overall and cancer-specific survival.
On the basis of this population-based cohort of stage IV colorectal cancer patients, palliative primary tumor resection was associated with improved overall and cancer-specific survival. Therefore, the dogma that an asymptomatic primary tumor never should be resected in patients with unresectable colorectal cancer metastases must be questioned.
评估在不可治愈的 IV 期结直肠癌患者中进行姑息性原发肿瘤切除术是否与改善生存相关。
对于不可治愈的 IV 期结直肠癌患者是否应切除无症状的原发肿瘤存在激烈争论。
在 1998 年至 2009 年间,在 Surveillance, Epidemiology, and End Results 数据库中确定了 IV 期结直肠癌患者。排除了接受转移性部位手术的患者。使用风险调整 Cox 比例风险回归模型和分层倾向评分方法,比较有和无姑息性原发肿瘤切除术的患者的总生存和癌症特异性生存。
总体而言,确定了 37793 例 IV 期结直肠癌患者。其中,23004 例(60.9%)接受了姑息性原发肿瘤切除术。行姑息性原发肿瘤切除术的患者比例从 1998 年的 68.4%下降至 2009 年的 50.7%(P < 0.001)。在倾向评分匹配后的 Cox 回归分析中,原发肿瘤切除术与总生存显著改善相关[死亡风险比(HR)=0.40,95%置信区间(CI)=0.39-0.42,P < 0.001]和癌症特异性生存(HR 死亡=0.39,95%CI=0.38-0.40,P < 0.001)。1998 年至 2009 年期间,姑息性原发肿瘤切除术的获益持续存在,总生存和癌症特异性生存的 HR 均等于或小于 0.47。
基于该 IV 期结直肠癌患者的人群队列,姑息性原发肿瘤切除术与总生存和癌症特异性生存的改善相关。因此,对于不可切除的结直肠癌转移患者,无症状原发肿瘤永远不应切除的教条必须受到质疑。